A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer by unknown
Siva et al. BMC Cancer 2014, 14:740
http://www.biomedcentral.com/1471-2407/14/740STUDY PROTOCOL Open AccessA prospective observational study of Gallium-68
ventilation and perfusion PET/CT during and after
radiotherapy in patients with non-small cell lung
cancer
Shankar Siva1,2*, Jason Callahan1, Tomas Kron1, Olga A Martin1, Michael P MacManus1,2, David L Ball1,2,
Rodney J Hicks1,2,3 and Michael S Hofman1,3Abstract
Background: Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers, and is the leading cause of
cancer deaths. Radiation therapy (RT), alone or in combination with chemotherapy, is the standard of care for
curative intent treatment of patients with locally advanced or inoperable NSCLC. The ability to intensify treatment
to achieve a better chance for cure is limited by the risk of injury to the surrounding lung.
Methods/Design: This is a prospective observational study of 60 patients with NSCLC receiving curative intent RT.
Independent human ethics board approval was received from the Peter MacCallum Cancer Centre ethics committee.
In this research, Galligas and Gallium-68 macroaggregated albumin (MAA) positron emission tomography (PET) imaging
will be used to measure ventilation (V) and perfusion (Q) in the lungs. This is combined with computed tomography
(CT) and both performed with a four dimensional (4D) technique that tracks respiratory motion. This state-of-the-art
scan has superior resolution, accuracy and quantitative ability than previous techniques. The primary objective of
this research is to observe changes in ventilation and perfusion secondary to RT as measured by 4D V/Q PET/CT.
Additionally, we plan to model personalised RT plans based on an individual’s lung capacity. Increasing radiation
delivery through areas of poorly functioning lung may enable delivery of larger, more effective doses to tumours
without increasing toxicity. By performing a second 4D V/Q PET/CT scan during treatment, we plan to simulate
biologically adapted RT depending on the individual’s accumulated radiation injury. Tertiary aims of the study are
assess the prognostic significance of a novel combination of clinical, imaging and serum biomarkers in predicting
for the risk of lung toxicity. These biomarkers include spirometry, 18 F-Fluorodeoxyglucose PET/CT, gamma-H2AX
signals in hair and lymphocytes, as well as assessment of blood cytokines.
Discussion: By correlating these biomarkers to toxicity outcomes, we aim to identify those patients early who
will not tolerate RT intensification during treatment. This research is an essential step leading towards the design
of future biologically adapted radiotherapy strategies to mitigate the risk of lung injury during dose escalation for
patients with locally advanced lung cancer.
Trials registration: Universal Trial Number (UTN) U1111-1138-4421.
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Local treatment failures are still a major cause for the
disappointing outcomes for patients with non-small
cell lung cancer (NSCLC) treated with radiotherapy.
Locoregional failures still occur in up to 37% of patients
[1], and is a major cause of the morbidity and mortality
related to this disease. To minimise the risk of failure, a
focus of current international research is radiotherapy
dose intensification. Efforts to intensify radiotherapy are
severely limited by the need to constrain dose to the
surrounding normal lung in order to preserve function
[2]. Unfortunately, acute lung injury secondary to RT in
the form of pneumonitis is a potentially debilitating
toxicity, sometimes leading to patient death. A recent
meta-analysis suggests that symptomatic pneumonitis
still occurs in 29.8% of patients and fatal pneumonitis in
1.9% [3]. However, currently used RT planning constraints
that are designed to limit the risk of pneumonitis are
based on evidence over a decade old [4]. These constraints
are based on population-based volumetric measurements
of total irradiated lung irrespective of regional variation of
function, and do not account for individual variation in
pulmonary physiology. Recent efforts to non-adaptively
dose-escalate without personalizing radiotherapy to the
individual’s risk of pneumonitis have met with limited or
no success [5]. On the other hand, it has been estimated
that tumour control probability (TCP, or likelihood of
cure) for conventional radiotherapy could be improved
by ~50% (from 19.9% to 28.7%) by adaptively intensifying
radiotherapy [6]. At present, an understanding of the
relationship between toxicity, radiation dose and volume
of irradiated lung is incomplete. Acquiring normal human
lung tissue after irradiation for pathobiological analysis
is associated with significant patient risk. It is therefore
imperative to establish in vivo functional imaging bio-
markers for early assessment, prediction and ultimately
avoidance of delayed organ dysfunction.
In-vivo biomarkers of radiation effect in lung
Clinical, radiographic, and lung function endpoints have
all been previously used to investigate the effects of
inhomogenous irradiation of partial lung volumes [7].
Pulmonary function tests (PFTs) are tools capable of
assessing global lung function as a whole organ. Reductions
in pulmonary function have been used as an objective
assessment of radiation-induced lung injury by several
groups [8-10]. In the setting of breast cancer and lymph-
oma, Theuws et al. [11] postulated a 1% reduction in PFT
for each 1-Gy increase in mean lung dose. Gergel et al.
[12] investigated radiation-induced lung changes after
irradiation of oesophageal cancers. This group found a
statistically significant correlation between the volume
of lung receiving between 7 – 10 Gy and reductions in
total lung capacity, vital capacity, and carbon monoxidediffusion capacity. However, in the case of centrally located
lung tumours, PFTs may improve post-irradiation due to
reinflation of lung segments obstructed and collapsed by
tumour. This has been previously reported in up to 40-50%
of patients with centrally located tumours [13,14].
Ventilation and perfusion (V/Q) imaging is an in-vivo
technique that measures regional lung function and may
be used to individualise lung radiotherapy. Assessment of
lung perfusion (Q) is particularly relevant to radiation-
induced lung damage as, along with pneumocytes, vascular
endothelium is considered one of the most radiation
sensitive tissue in the lungs [15]. Planar scintigraphy
using 99mTc-labeled macroaggregated albumin (MAA) is a
long-established imaging standard for functional lung
perfusion evaluation. Single positron emission computed
tomography (SPECT) is a more modern functional assess-
ment technique enabling three dimensional imaging [16],
which has lead to improved sensitivity, specificity, and
reproducibility [17-19]. The advent of hybrid SPECT/CT
devices further improved diagnostic accuracy by enabling
anatomic characterization of scintigraphic abnormalities
[20]. Perfusion SPECT/CT has been demonstrated to im-
prove functional lung avoidance during lung radiotherapy
planning by several groups [21-23].
PET/CT for ventilation and perfusion imaging
PET/CT offers a unique opportunity to further improve
the image quality of functional lung imaging owing to its
superior sensitivity for detecting radioactive substances,
higher spatial and temporal resolution and commercial
availability of respiratory gated 4D acquisition systems
[24]. By substituting the conventional 99mTc radionuclide
with 68Ga, a positron emitter, it is now possible to perform
CT co-registered perfusion 68Ga-macroaggregated albumin
(MAA) PET [25], Figure 1. We have previously reported
that non-gated 3D V/Q PET/CT has superior image quality
and provides fully tomographic images with potential for
better regional quantitation of lung function as compared
to V/Q SPECT/CT in the context of pulmonary embolism
[26]. We have further improved this technique through the
use of respiratory gated (4D) acquisition, which can reduce
blurring caused by respiration motion and resultant artefact
at the lung bases [27,28]. We have also described method-
ology for deformable image registration in the context of
Galligas ventilation PET and CT ventilation datasets. The
use of 4D-V/Q PET imaging allows for fully quantitative as-
sessment of regional injury during lung irradiation (Figure 2).
We aim to use this novel imaging technique to inform
radiotherapy planning firstly by adaptation of RT planning
pre-treatment to respect the individual patient’s lung toler-
ance. This may enable the treatment of a subgroup of pa-
tients that would not be considered eligible for curative
RT based on population-based risk estimates of entire
lung. Secondly, we aim to simulate adaptation of RT
Figure 1 MAA-perfusion PET (left), contemporaneous CT (middle), and co-registered perfusion PET/CT, in a patient with a right upper
lobe T3 squamous cell carcinoma.
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alise RT delivery in response to individual lung injury.
Methods/Design
This is a prospective single cohort observational study
investigating in-vivo biomarkers radiation toxicity in
n = 60 patients with NSCLC. The trial schema is demon-
strated in Figure 3.
Trial inclusion criteria
 Age ≥ 18 years;
 Written informed consent has been provided.Figure 2 V/Q PET/CT, a) CT alone, b) fused PET/CT, c) 3D volume rend
PET/CT. A patient with a large upper lobe NSCLC (image a), showing
distal to the tumour (images b, c, and d). FDG-PET scan performed for cancer staging
 Patients receiving curative intent radiotherapy for
non-small cell lung cancer.
 Minimum dose of radiotherapy prescribed is 60Gy
with or without chemotherapy
 ECOG performance status 0–2 inclusive
Trial exclusion criteria
 Participant is not able to tolerate supine position on
PET/CT bed for the duration of the PET/CT
acquisitions, is not cooperative, or needs continuous
nursing (e.g. patient from Intensive Care Unit).ered (VR) CT ventilation reconstruction d) 3D fused VR perfusion
both ventilation deficits distal to tumour and perfusion deficits
Figure 3 Trial schema.
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 Lung Spirometry: reversibility in FEV1 > 200mls
and > 15% predicted change after bronchodilator
Trial objectives
The primary objective of this study is to evaluate the
pattern of regional pulmonary perfusion and ventilation
as demonstrated on V/Q PET/CT before, during and
after a course of radiotherapy in patients with NSCLC.
The secondary objectives are to:
1. Assess whether serial changes in global lung
ventilation and perfusion as demonstrated on PFTs
are related to regional lung ventilation and perfusion
changes as demonstrated on V/Q PET/CT
2. Describe the quality of the co-registration of V/Q
PET/CT with i) respiratory attenuated concurrent
4DCT or with ii) conventional CT alone.
3. Describe a dose/response relationship between
delivered dose and ventilation/perfusion changes
demonstrated on V/Q PET/CT
4. Whether ventilation/perfusion mismatches and lung
density demonstrated on baseline V/Q PET/CT are
correlated with baseline PFT parameters.
5. To simulate administration of biologically adapted
radiotherapy techniques personalised to individual
lung function based on information gained from
V/Q PET/CT at baseline and at mid-treatment
The exploratory objectives are to assess:
1. Whether mid-treatment or post-treatment changes in
pulmonary perfusion measured by V/Q PET/CT are
associated with delayed development of inflammatory
changes in the radiation field as determined by FDG
PET/CT at 3 months post-treatment.
2. Whether mid-treatment or post-treatment changes
in pulmonary perfusion measured by V/Q PET/CT
are associated with delayed disease control in the
radiation field at 3 months post-treatment as
determined by metabolic response in tumour on
FDG PET/CT.3. Whether radiological post-treatment changes in
perfusion, density or metabolism in either lung or
tumour are associated with the development of
clinical toxicity
4. Whether changes in regional ventilation and
perfusion demonstrated on V/Q PET/CT is different
between patients with and without radiological
evidence of fibrosis.
Biologically adaptive planning
Patients in this study will be treated with conventional
radiotherapy, 60 Gy in 30 fractions over six weeks. Func-
tionally adaptive planning tailored to ventilated and per-
fused lung volumes will be performed at 2 timepoints:
1. Simulated alternative plan based on baseline V/Q
PET/CT functional volumes of lung
2. Simulated biologically adapted RT based on the
week-four interim V/Q PET/CT information;
 For all patients: − an accelerated dose-schedule
in the final week of RT onwards will be simulated,
delivering 1.8Gy bi-daily to an isotoxic dose
satisfying original Organ at Risk (OAR) constraints.
Plans will be created using conventional anatomical
methods using CT information alone.
 For patients without significant perfusion
deficits: − an accelerated dose-escalated schedule
in the final week of RT onwards will be simulated,
delivering 1.8Gy bi-daily to an isotoxic dose
satisfying original Organ at Risk (OAR) constraints.
Plans will be created using functional lung volumes
dervied from the V/Q PET/CT.Organ at Risk (OAR) dose measures for which limits will
be set include: Lung: volume receiving 20 Gy, 30 Gy and
mean dose, Spinal canal: maximum dose, Oesophagus:
volume receiving 50 Gy, 60 Gy, mean and maximum dose,
Heart: volume receiving 40 Gy, 60 Gy and mean dose.
For each model, we will record and analyse the following
dose parameters:
 Tumour control probability (TCP) and normal
tissue complication probability (NTCP)
 The maximum, mean and standard deviation of
escalated dose achievable
 OAR doses at each dose increment and OAR
preventing escalation to the next dose increment
Statistical considerations
The proposed sample size was calculated based on the
capacity to detect the rate of clinical pneumonitis in
those patients not demonstrating perfusion deficits dur-
ing radiotherapy. Based on initial findings, it is expected
that 60% of patients will have no evidence of perfusion
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that these patients to have an ~10% rate of clinical pneu-
monitis at 1 year, as compared with historical clinical
pneumonitis rates of ~30% at 1 year for patients treated
with curative intent RT. With a sample size of 60, a
3 year-accrual period, and a minimum of 1-year follow-up
for toxicity assessment, then allowing for a 2-sided type I
error rate of 0.05 the power of the study to distinguish
between the two groups is equal to 80%.
Translational substudy
Participation in a translational substudy will be offered
for up to 45 patients of the total 60 patients recruited
into this trial.
Inflammatory cytokine release
Cytokine release in response to ionizing radiation is a
documented phenomenon and may play a major role in
subsequent radiation induced lung toxicity (reviewed in
[29-33]. Fractionated radiation creates a constant complex
stress response and a cytokine profile is different to that
induced by a single radiation dose [34]. RT-related plasma
concentrations of one or more cytokines in humans have
correlated with lung toxicity. Transforming growth factor
(TGF)-β1 [35-38], interleukin (IL)-6 and IL-10 [39,40]
during RT have been suggested as possible risk markers in
these studies. However, other studies have reported
contradictory or negative findings [41,42]. In this study,
we propose to analyse a partial selection of cytokines
from a commercial human inflammatory cytokine panel
of 22 cytokines. The rationale for the composition of 22
potential biomarkers for lung tissue toxicity is based on
several published reports dissecting inflammatory and
radiation response.
Assessment of γ-H2AX signal as a biodosimeter
DNA is the most significant target of radiation exposure
for survival and carcinogenesis. An early response of
the cell to ionizing radiation-induced DNA damage is
a phosphorylation of a histone protein H2AX, forming
γ-H2AX [43]. Hundreds to thousands of γ-H2AX mole-
cules surround one DSB to form a focus which functions
to open the chromatin structure and to serve as a plat-
form for the accumulation of many factors involved in the
DDR [44]. These sites can be marked with anti-γ-H2AX
antibodies with fluorescent “tags”. The number of foci
per cell is proportional to the radiation dose and follows
well-studied kinetics in normal tissues [45,46]. The γ-
H2AX assay is considered to be the most sensitive modern
assay for DSB detection and response to radiation doses
as low as 1 mGy. This sensitivity allows detection of
radiotherapy-induced DNA damage in situ in human
lymphocytes [47]. In addition, the assay has another
important feature; it measures a change which occursvery quickly with the maximal response is at 30 minutes
to 1 hour after irradiation. Dose-dependent responses
and persistence of foci make γ-H2AX assay a good bio-
dosimeter for exposure of humans to ionizing radiation
during radiological diagnostics or therapeutic treatments
[47-49]. The application of this assay in the case of homo-
geneous total body irradiation is straightforward and relies
on the measurement of the average number of γH2AX
foci per cell. An approach has also been suggested to apply
γH2AX assay as a biodosimeter for partial body irradiation
to evaluate the irradiated fraction of the blood volume and
the dose received by that fraction [50]. The approach
exploits such measures as the fraction of lymphocytes
with γH2AX foci and the average number of γH2AX
foci per cell in this fraction. In the proposed study we
plan to analyse distributions of cells (lymphocytes) with
respect to the number of γH2AX foci as a further devel-
opment of this approach. We expect that the analysis of
distributions will allow us to deconvolute irradiated and
non-irradiated subpopulations of lymphocytes and to
estimate the fraction and the dose for irradiated
subpopulation.
Assessment of the abscopal effect using γ-H2AX
A novel approach to assessment of an individual patient
risk from lung radiotherapy is the assessment of ‘out-
of-field’ radiation induced changes. The appearance of
genome abnormalities and loss of viability in cells other
than those directly hit with ionizing radiation (IR) is a
well-documented process known as the radiation-induced
bystander effect [51]. An important question is whether
such effects demonstrated in vitro also exist in vivo. In
classic radiobiology there is the so-called abscopal (out-of
field or distant) effect, where irradiation of one organ
results in a change in another, unirradiated organ [52].
Although possibly caused by scatter from the main
radiation source, abscopal effects may also suggest the
presence of bystander-like processes in whole organisms.
Inflammatory mediators, such as chemokines, cytokines,
and prostaglandins [53] as well as reactive oxygen and
nitrogen species [54,55] mediate this effect. DNA damage
has been reported in noncancerous cells neighboring
tumors [56,57] for example, in normal liver tissue adjacent
to hepatocellular carcinoma [58]. We hypothesize that
the intensity of ‘out-of-field’ radiation induced changes
demonstrated during and after a course of radiotherapy
will predict for individual patient risk for developing
lung radiation toxicity. The first step for ‘proof of principle’
is to document abscopal changes through detection of
γ-H2AX foci within non-irradiated (bystander) tissues
(hair follicles from the eyebrows of participating patients).
These changes will be compared (when available) to
changes in chest hairs from within the irradiated portal
(to act as a ‘control’).
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Up to 45 patients enrolled into the study will be invited
to participate in this translational substudy. In addition
to the investigations mandated in the protocol, blood
samples and hair follicles will be collected and processed
at the following timepoints:
 At baseline before treatment (this will be taken at
the time of blood collection prior to injection of the
Ga-68 tracer for the baseline PET scan)
 1-hour after the first fraction of radiotherapy
 No longer than 1 hour before the second fraction
radiotherapy (approximately 24 hours after the first
fraction of radiotherapy)
 Mid-treatment at 4 weeks. (this will be taken at the
time of blood collection prior to injection of the
Ga-68 tracer for the mid-treatment PET scan)
 3-months post-treatment (this will be taken at the
time of blood collection prior to injection of the
Ga-68 tracer for the post-treatment PET scan)
To process the blood sample for biodosimetric ana-
lysis, the following methodology will be used:
 Collection of lymphocytes by Ficoll gradient
separation.
 Fixing and immunofluorescent staining using a mouse
γ-H2AX primary antibody (Abcam) and secondary
anti-mouse antibody labelled with Alexa488
fluorescent dye (Millipore).
 Imaging with confocal microscopy and automatic
analysis of γ-H2AX positive cells.
To process the blood samples for assessment of cyto-
kine release, the following methodology will be used:
 Serum will be separated and frozen at −80°C until
analysis.
 Analysis will be performed using a multiplex ELISA
based platform
To process the hair follicles for assessment of by-
stander radiation effect, the following methodology will
be used:
 3 hair follicles will be plucked from the eyebrow
region of participating patients at each time-point.
 The hairs will be fixed, immunostained for γ-H2AX,
and processed for microscopy and analysis.
Discussion
Lung cancer remains the leading cause of cancer death
in Australia and RT is a primary treatment modality
for the most common form, NSCLC. Current evidencesuggests that the ideal dose is a uniform 60Gy prescribed
over 6 weeks to the majority of patients [59]. The two
major outcomes of this research will be the generation of
biologically personalised RT plans adapted to individual
patient lung tolerance, and data regarding clinically
useful early biomarkers to predict for patient outcomes.
4D-68Ga-V/Q PET/CT represents a novel imaging bio-
marker for lung function and allows for highly accurate
measurements of lung ventilation and perfusion. This
clinical trial investigates the ability to biologically adapt
RT in patients with NSCLC using a state-of-the-art
combination of clinical, imaging and serum biomarker
analyses in order to achieve the aims of our research,
which are: a) individualising RT to maximise the prob-
ability of curing lung cancer, b) increase the number of
patients who may be suitable for curative radiotherapy
by planning radiotherapy delivery to avoid functional
lung, c) determine models for targeting dose intensified
radiation whilst sparing the important functioning lung
surrounding the tumour and d) determining the pro-
portion of patients who could receive intensified doses
safely within the constraints of surrounding organs, and
how high these intensified doses would be. Furthermore,
the major implications of establishing interim prognostic
markers during RT include: e) the validation of prognostic
indices to predict clinical behaviour and assess toxicity
risk and f) providing an insight into normal lung behav-
iour during RT, thereby presenting an opportunity to
enhance patient management, including the delivery of
individually adapted RT. At the successful completion of
this trial we plan to advance this research by implement-
ing a clinical trial of biologically adaptive radiotherapy that
is personalised to both the patient’s pre-treatment regional
lung function and observed functional lung injury during
treatment.
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